AR093017A1 - MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO - Google Patents

MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO

Info

Publication number
AR093017A1
AR093017A1 ARP130103735A ARP130103735A AR093017A1 AR 093017 A1 AR093017 A1 AR 093017A1 AR P130103735 A ARP130103735 A AR P130103735A AR P130103735 A ARP130103735 A AR P130103735A AR 093017 A1 AR093017 A1 AR 093017A1
Authority
AR
Argentina
Prior art keywords
alkyl
pyridyl
optionally substituted
pyridazyl
pyrazinyl
Prior art date
Application number
ARP130103735A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR093017A1 publication Critical patent/AR093017A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Comprende, además, un método para tratar o mejorar un síndrome, un trastorno o una enfermedad, en donde el síndrome, el trastorno o la enfermedad es artritis reumatoide o soriasis. La presente comprende, además, un método para modular la actividad de RORgt en un mamífero mediante la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de la reivindicación 1. Reivindicación 1: Un compuesto de la fórmula (1), en donde: R¹ es pirrolilo, pirazolilo, imidazolilo, triazolilo, tiazolilo, piridilo, N-óxido de piridilo, pirazinilo, pirimidinilo, piridazilo, piperidinilo, quinazolinilo, cinolinilo, benzotiazolilo, indazolilo, tetrahidropiranilo, tetrahidrofuranilo, furanilo, fenilo, oxazolilo, isoxazolilo, tiofenilo, benzoxazolilo, bencimidazolilo, indolilo, tiadiazolilo, oxadiazolilo o quinolinilo; en donde el piridilo, N-óxido de piridilo, pirazinilo, pirimidinilo, piridazilo, piperidinilo, quinazolinilo, cinolinilo, benzotiazolilo indazolilo, imidazolilo, fenilo, tiofenilo, benzoxazolilo, benzimidazolilo, indolilo, quinolinilo y pirazolilo están sustituidos opcionalmente con alquilo C(O)C₁₋₄, C₍O₎NH₂, alquilo C(O)NHC₁₋₂, C₍O₎N₍ₐₗqᵘⁱₗₒ C₁₋₂)₂, alquilo NHC(O)C₁₋₄, alquilo NHSO₂C₁₋₄, alquilo C₁₋₄, CF₃, CH₂CF₃, Cl, F, -CN, alquilo OC₁₋₄, N(alquilo C₁₋₄)₂, -(CH₂)₃OCH₃, alquilo SC₁₋₄, OH, CO₂H, alquilo CO₂C₁₋₄, C₍O₎CF₃, SO₂CF₃, OCF₃, OCHF₂, SO₂CH₃, SO₂NH₂, alquilo SO₂NHC₁₋₂, SO₂N(alquilo C₁₋₂)₂, C(O)NHSO₂CH₃, o OCH₂OCH₃; y están sustituidos opcionalmente con hasta dos sustituyentes adicionales seleccionados independientemente del grupo que consiste en Cl, alquilo C₁₋₂, SCH₃, alquilo OC₁₋₂, CF₃, -CN, y F; y en donde el triazolilo, oxazolilo, isoxazolilo, pirrolilo, y tiazolilo están sustituidos opcionalmente con hasta dos sustituyentes seleccionados independientemente del grupo que consiste en SO₂CH₃, SO₂NH₂, C(O)NH₂, -CN, alquilo OC₁₋₂, (CH₂)₍₂₋₃₎OCH₃, SCH₃, CF₃, F, Cl, y alquilo C₁₋₂; y el tiadiazolilo y oxadiazolilo están sustituidos opcionalmente con alquilo C₁₋₂; y el piridilo, N-óxido de piridilo, pirimidinilo, piridazilo y pirazinilo están sustituidos opcionalmente con hasta tres sustituyentes adicionales seleccionados independientemente del grupo que consiste en alquilo C(O)NHC₁₋₂, C₍O₎N₍ₐₗqᵘⁱₗₒ C₁₋₂)₂, alquilo NHC(O)C₁₋₄, alquilo NHSO₂C₁₋₄, C₍O₎CF₃, SO₂CF₃, alquilo SO₂NHC₁₋₂, SO₂N(alquilo C₁₋₂)₂, C(O)NHSO₂CH₃, SO₂CH₃, SO₂NH₂, C(O)NH₂, -CN, alquilo OC₁₋₄, (CH₂)₍₂₋₃₎OCH₃, alquilo SC₁₋₄, CF₃, F, Cl y alquilo C₁₋₄; R² es triazolilo, piridilo, piridilo-N-óxido, pirazolilo, pirimidinilo, oxazolilo, isoxazolilo, azetidin-3-ilo, N-acetil-azetidin-3-ilo, N-metilsulfonil-azetidin-3-ilo, N-Boc-azetidin-3-ilo, N-acetil piperidinilo, 1-H-piperidinilo, N-Boc-piperidinilo, N-alquilo C₁₋₃-piperidinilo, tiazolilo, piridazilo, pirazinilo, 1-(3-metoxipropilo)-imidazolilo, tiadiazolilo, oxadiazolilo, o imidazolilo; en donde el imidazolilo está sustituido, opcionalmente, con hasta tres sustituyentes adicionales seleccionados independientemente del grupo que consiste en alquilo C₁₋₂, SCH₃, alquilo OC₁₋₂, CF₃, -CN, F y Cl; y el piridilo, piridilo-N-óxido, pirimidinilo, piridazilo y pirazinilo están sustituidos, opcionalmente con hasta tres sustituyentes adicionales seleccionados independientemente del grupo que consiste en SO₂CH₃, SO₂NH₂, C(O)NH₂, -CN, alquilo OC₁₋₂, (CH₂)₍₂₋₃₎OCH₃, SCH₃, CF₃, F, Cl o alquilo C₁₋₂; y el triazolilo, tiazolilo, oxazolilo e isoxazolilo están sustituidos, opcionalmente, con hasta dos sustituyentes seleccionados independientemente del grupo que consiste en SO₂CH₃, SO₂NH₂, C(O)NH₂, -CN, alquilo OC₁₋₂, (CH₂)₍₂₋₃₎OCH₃, SCH₃, CF₃, F, Cl y alquilo C₁₋₂; y el tiadiazolilo y oxadiazolilo están sustituidos, opcionalmente, con alquilo C₁₋₂; y el pirazolilo está sustituido opcionalmente con hasta tres grupos de CH₃; R³ es H, OH, OCH₃ o NH₂; R⁴ es H, o F; R⁵ es H, Cl, -CN, CF₃, alquilo SC₁₋₄, alquilo OC₁₋₄, OH, alquilo C₁₋₄, N(CH₃)OCH₃, NH(alquilo C₁₋₄), N(alquilo C₁₋₄)₂, o 4-hidroxi-piperidinilo; R⁶ es fenilo, piridilo, benzotiofenilo, tiofenilo, pirimidinilo, piridazilo o pirazinilo; en donde el pirimidinilo, piridazilo o pirazinilo están sustituidos opcionalmente con Cl, F, CH₃, SCH₃, alquilo OC₁₋₄, -CN, CONH₂, SO₂NH₂ o SO₂CH₃; y en donde el fenilo o el piridilo está opcionalmente sustituido hasta dos veces con OCF₃, alquilo SO₂C₁₋₄, CF₃, CHF₂, pirazolilo, triazolilo, imidazolilo, tetrazolilo, oxazolilo, tiazolilo, alquilo C₁₋₄, cicloalquilo C₃₋₄, alquilo OC₁₋₄, N(CH₃)₂, SO₂NH₂, SO₂NHCH₃, SO₂N(CH₃)₂, CONH₂, CONHCH₃, CON(CH₃)₂, Cl, F, -CN, CO₂H, OH, CH₂OH, alquilo NHCOC₁₋₂, alquilo COC₁₋₂, SCH₃, alquilo CO₂C₁₋₄, NH₂, alquilo NHC₁₋₂ o OCH₂CF₃; en donde la selección de cada sustituyente opcional es independiente y en donde el pirazolilo, triazolilo, imidazolilo, tetrazolilo, oxazolilo y tiazolilo están opcionalmente sustituidos con CH₃; R⁷ es H, Cl, -CN, alquilo C₁₋₄, alquilo OC₁₋₄, CF₃, OCF₃, OCHF₂, alquilo OCH₂CH₂OC₁₋₄, CF₃, SCH₃, alquilo C₁₋₄, NA¹A², alquilo CH₂OC₂₋₃NA¹A², NA¹A², C(O)NA¹A², alquilo CH₂NHC₂₋₃NA¹A², alquilo CH₂N(CH₃)C₂₋₃NA¹A², alquilo NHC₂₋₃NA¹A², alquilo N(CH₃)C₂₋₄NA¹A², alquilo OC₂₋₄NA¹A², alquilo OC₁₋₄, OCH₂-(1-metil)-imidazol-2-ilo, fenilo, tiofenilo, furilo, pirazolilo, imidazolilo, piridilo, piridazilo, pirazinilo o pirimidinilo; en donde el fenilo, tiofenilo, furilo, pirazolilo, imidazolilo, piridilo, piridazilo, pirazinilo y pirimidinilo están sustituidos opcionalmente con hasta tres sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, CH₃, CF₃ y OCH₃; A¹ es H o alquilo C₁₋₄; A² es H, alquilo C₁₋₄, alquilo C₁₋₄alquilo C₁₋₄, alquilo C₁₋₄OH, alquilo C(O)C₁₋₄ o alquilo OC₁₋₄; o A¹ y A² podrían tomarse en conjunto con su nitrógeno unido para formar un anillo seleccionado del grupo de fórmulas (2); Rᵃ es H, alquilo OC₁₋₄, CH₂OH, NH(CH₃), N(CH₃)₂, NH₂, CH₃, F, CF₃, SO₂CH₃ o OH; Rᵇ es H, CO₂C(CH₃)₃, alquilo C₁₋₄, alquilo C(O)C₁₋₄, alquilo SO₂C₁₋₄, CH₂CH₂CF₃, CH₂CF₃, CH₂-ciclopropilo, fenilo, CH₂-fenilo o cicloalquilo C₃₋₆; R⁸ es H, alquilo C₁₋₃, alquilo OC₁₋₃, CF₃, NH₂, NHCH₃, -CN o F; R⁹ es H o F; y sales farmacéuticamente aceptables de estos; siempre que (4-cloro-2-metoxi-3-(4-(trifluorometil)bencil)quinolin-6-il)bis(1,2,5-trimetil-1H-imidazol-4-il)metanol, N-(2-((3-(4-(1H-pirazol-1-il)bencil)-6-((4-clorofeniI)(hidroxi)(1-metil-1H-imidazol-5-il)metil)-4-hidroxiquinolin-2-il)oxi)etil)acetamida y (3-(4-(1H-pirazol-1-il)bencil)-4-cloro-2-(4-metilpiperazin-1-il)quinolin-6-il)(1-metil-1H-imidazol-5-il)(6-(trifluorometil)piridin-3-il)metanol se excluyan de la reivindicación.
ARP130103735A 2012-10-16 2013-10-15 MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO AR093017A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261714419P 2012-10-16 2012-10-16
US201261725528P 2012-11-13 2012-11-13
US201361782257P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR093017A1 true AR093017A1 (es) 2015-05-13

Family

ID=49546611

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103735A AR093017A1 (es) 2012-10-16 2013-10-15 MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO

Country Status (38)

Country Link
US (1) US9290476B2 (es)
EP (1) EP2909192B1 (es)
JP (1) JP6466335B2 (es)
KR (1) KR20150070347A (es)
CN (1) CN105209453B (es)
AR (1) AR093017A1 (es)
AU (1) AU2013331496B2 (es)
BR (1) BR112015008308A2 (es)
CA (1) CA2888210C (es)
CL (1) CL2015000945A1 (es)
CR (1) CR20150193A (es)
CY (1) CY1119234T1 (es)
DK (1) DK2909192T3 (es)
EA (1) EA026415B1 (es)
EC (1) ECSP15015022A (es)
ES (1) ES2632269T3 (es)
GT (1) GT201500093A (es)
HK (1) HK1213248A1 (es)
HR (1) HRP20171082T1 (es)
HU (1) HUE035335T2 (es)
IL (1) IL237866B (es)
LT (1) LT2909192T (es)
ME (1) ME02794B (es)
MX (1) MX358508B (es)
MY (1) MY189505A (es)
NI (1) NI201500053A (es)
NZ (1) NZ706775A (es)
PE (1) PE20150778A1 (es)
PH (1) PH12015500817B1 (es)
PL (1) PL2909192T3 (es)
PT (1) PT2909192T (es)
RS (1) RS56283B1 (es)
SG (1) SG11201502369XA (es)
SI (1) SI2909192T1 (es)
TW (1) TWI606045B (es)
UY (1) UY35084A (es)
WO (1) WO2014062658A1 (es)
ZA (1) ZA201503418B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014019476A8 (pt) * 2012-02-13 2017-07-11 Hoffmann La Roche Novos derivados de imidazolilcetona
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JP6467404B2 (ja) 2013-03-14 2019-02-13 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７モジュレーター
EP3044219A1 (en) * 2013-09-09 2016-07-20 Bristol-Myers Squibb Company Rorgamma modulators
KR20160068956A (ko) * 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
CN105829294B (zh) * 2013-10-15 2018-11-09 詹森药业有限公司 ROR-γ-T的与亚甲基连接的喹啉基调节剂
BR112016008257A2 (pt) * 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de roryt de álcool quinolínico secundário
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) * 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) * 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2953637C (en) * 2014-05-28 2022-11-29 Glaxosmithkline Intellectual Property Development Limited Piperazine derivatives as ror-gamma modulators
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
AP2017009733A0 (en) 2014-09-12 2017-02-28 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
EA202190886A1 (ru) 2018-09-28 2021-09-07 Янссен Фармацевтика Нв Модуляторы моноацилглицерин-липазы
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN114555596A (zh) 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
AU2020377114A1 (en) * 2019-10-31 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Acid addition salt of RORγ regulator
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
AU2021266148A1 (en) 2020-04-30 2023-01-05 Idorsia Pharmaceuticals Ltd Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators
CN112939974B (zh) * 2021-03-11 2023-10-20 中山大学 一种氮杂苯并薁衍生物的制备方法
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
WO2023072924A1 (en) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
KR20240090693A (ko) 2021-10-28 2024-06-21 이도르시아 파마슈티컬스 리미티드 Ccr6 수용체 조절인자

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772U (es) 1971-08-02 1973-03-31
EP0062001B1 (de) 1981-03-24 1987-05-27 Ciba-Geigy Ag Acyl-chinolinonderivate, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Präparate und ihre Verwendung
US4910327A (en) 1982-05-25 1990-03-20 American Cyanamid Company Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid: dialkyl 3-(substituted)phenylaminobut-2-ene-dioates and methods for the preparation thereof
US4656283A (en) 1982-05-25 1987-04-07 American Cyanamid Company Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid
PT79699B (en) 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
FR2634483B2 (fr) 1987-12-29 1994-03-04 Esteve Labor Dr Derives des acides 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinoleine-3-carboxyliques, leur preparation et leur application en tant que medicaments
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
EP0709377B1 (en) 1994-10-27 1999-09-29 Asahi Glass Company Ltd. Process for producing quinolin-2-yl benzoic acid compounds
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
WO1997044339A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP4209472B2 (ja) * 1997-06-02 2009-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 平滑筋細胞増殖のインヒビターとしての（イミダゾール−５−イル）メチル−２−キノリノン誘導体
CA2309882A1 (en) 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
FR2776388B1 (fr) 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
AU762423B2 (en) 1998-07-06 2003-06-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors with In Vivo radiosensitizing properties
SI1094815T1 (en) * 1998-07-06 2004-04-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
JP2000169451A (ja) 1998-09-30 2000-06-20 Kyorin Pharmaceut Co Ltd ６，７―ジ置換キノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
UA71592C2 (uk) 1998-12-23 2004-12-15 Янссен Фармацевтика Н.В. Похідні 1,2-анельованого хіноліну, спосіб їх одержання (варіанти), фармацевтична композиція, що їх містить, проміжна сполука та спосіб її одержання
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
AU2124800A (en) 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
CA2396865C (en) 2000-02-04 2009-04-14 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
ATE375794T1 (de) 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
EP1263437A2 (en) 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030022918A1 (en) 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
US20030186925A1 (en) 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
US20030027808A1 (en) 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397256A1 (en) 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
EP1261342A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
WO2001064199A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
CA2397253A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
JP2003525255A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
EP1261348A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
JP2003525234A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US6844357B2 (en) 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
US6624159B2 (en) 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE60105614T2 (de) 2000-07-12 2005-10-06 Pharmacia & Upjohn Co., Kalamazoo Oxazinochinolone für die behandlung viraler infektionen
EP1322650B1 (en) 2000-09-25 2008-09-24 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2001293847B2 (en) 2000-10-02 2007-05-24 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists
ES2261523T3 (es) 2000-11-28 2006-11-16 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
EP1365763B1 (en) 2001-02-15 2008-11-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
CA2433467A1 (en) 2001-03-01 2002-09-12 Joseph W. Strohbach Substituted quinolinecarboxamides as antiviral agents
WO2002085364A1 (en) 2001-04-25 2002-10-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating cachexia
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
AU2002350244A1 (en) 2001-12-20 2003-07-09 Pharmacia And Upjohn Company Pyridoquinoxaline antivirals
US6686356B2 (en) 2001-12-20 2004-02-03 Pharmacia & Upjohn Company Pyridoquinoxaline antivirals
KR101061561B1 (ko) 2002-03-29 2011-09-02 얀센 파마슈티카 엔.브이. 대사자극성 글루타메이트 수용체 리간드로서 방사능표지된 퀴놀린 및 퀴놀리논 유도체 및 그의 용도
US7358249B2 (en) 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
WO2004019932A1 (en) 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
GB0222516D0 (en) 2002-09-27 2002-11-06 Karobio Ab Novel compounds
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1687277B1 (en) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
NZ547193A (en) 2003-12-05 2010-03-26 Janssen Pharmaceutica Nv 6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
UA91007C2 (ru) 2003-12-10 2010-06-25 Янссен Фармацевтика Н.В. Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
DE602005016890D1 (de) 2004-01-23 2009-11-12 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
EA011572B9 (ru) 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
JP2005225250A (ja) 2004-02-10 2005-08-25 Murakami Corp 車載用監視装置
UA86237C2 (uk) 2004-06-30 2009-04-10 Янссен Фармацевтика Н.В. Похідні заміщеного 2-алкілхіназолінону як інгібітори parp
RU2424232C2 (ru) 2004-08-04 2011-07-20 Мейдзи Сейка Кайся, Лтд. Производные хинолина и инсектициды, включающие их в качестве активного ингредиента
KR100686531B1 (ko) 2004-08-31 2007-02-23 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법
DK2362218T3 (en) 2004-11-05 2014-11-17 Janssen Pharmaceutica Nv Methods for monitoring the effectiveness of farnesyl transferase
JO2855B1 (en) 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
WO2007088978A1 (ja) 2006-02-03 2007-08-09 Meiji Seika Kaisha, Ltd. 新規キノリン誘導体およびこれを有効成分として含有する農園芸用殺菌剤
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
ES2393132T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteína quinasa de triazolopiridazina
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20100184803A1 (en) 2007-03-09 2010-07-22 Link Medicine Corporation Treatment of Lysosomal Storage Diseases
MX2009012623A (es) 2007-05-21 2009-12-11 Sgx Pharmaceuticals Inc Moduladores de cinasa heterociclicos.
CN101143845B (zh) 2007-10-15 2010-08-25 中国药科大学 取代喹啉甲酰胍衍生物、其制备方法及其医药用途
BRPI0906927A2 (pt) 2008-01-18 2015-07-21 Allergan Inc Compostos de substituída-aril-(imidazol)-metil)-fenila como moduladores seletivos de subtipo de receptores alfa 2b e/ou alfa 2c adrenérgicos
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
AU2009246601A1 (en) 2008-05-13 2009-11-19 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
WO2010068296A1 (en) 2008-12-11 2010-06-17 Stiefel Laboratories, Inc. Piperazine carboxamidines as antimicrobial agents
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
CN101899011B (zh) 2009-05-26 2013-01-16 北京大学 氨基二硫代甲酸酯类化合物、其制备方法和应用
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
SG176986A1 (en) 2009-06-25 2012-02-28 Amgen Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
JP2013523192A (ja) 2010-04-15 2013-06-17 クロモセル コーポレーション 苦味を低減または排除する化合物、組成物、および方法
EP2638014B1 (en) * 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
EP2678052B1 (en) 2011-02-24 2018-09-26 Emory University Jab1 blocking compositions for ossification and methods related thereto
KR101964478B1 (ko) 2011-04-28 2019-04-01 니뽄 다바코 산교 가부시키가이샤 아미드 화합물 및 그의 의약 용도
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
KR20150070347A (ko) 2015-06-24
JP2015536320A (ja) 2015-12-21
HUE035335T2 (en) 2018-05-02
DK2909192T3 (en) 2017-08-07
PH12015500817A1 (en) 2015-06-08
ES2632269T3 (es) 2017-09-12
HRP20171082T1 (hr) 2017-10-06
CA2888210A1 (en) 2014-04-24
EA201590736A1 (ru) 2015-09-30
TW201427969A (zh) 2014-07-16
SI2909192T1 (sl) 2017-08-31
EA026415B1 (ru) 2017-04-28
UY35084A (es) 2014-04-30
ECSP15015022A (es) 2016-01-29
EP2909192A1 (en) 2015-08-26
EP2909192B1 (en) 2017-05-17
MY189505A (en) 2022-02-16
SG11201502369XA (en) 2015-05-28
HK1213248A1 (zh) 2016-06-30
CL2015000945A1 (es) 2015-08-28
JP6466335B2 (ja) 2019-02-06
CR20150193A (es) 2015-05-18
PL2909192T3 (pl) 2017-09-29
MX358508B (es) 2018-08-22
AU2013331496B2 (en) 2017-07-27
RS56283B1 (sr) 2017-12-29
LT2909192T (lt) 2017-07-10
US20140107094A1 (en) 2014-04-17
TWI606045B (zh) 2017-11-21
WO2014062658A1 (en) 2014-04-24
IL237866B (en) 2018-05-31
PE20150778A1 (es) 2015-05-23
PT2909192T (pt) 2017-08-04
ME02794B (me) 2018-01-20
AU2013331496A1 (es) 2015-04-09
US9290476B2 (en) 2016-03-22
GT201500093A (es) 2017-09-26
NI201500053A (es) 2020-03-18
WO2014062658A8 (en) 2014-07-10
PH12015500817B1 (en) 2015-06-08
NZ706775A (en) 2018-10-26
CN105209453B (zh) 2017-06-20
CY1119234T1 (el) 2018-02-14
ZA201503418B (en) 2017-11-29
MX2015004783A (es) 2015-08-14
BR112015008308A2 (pt) 2017-12-05
CA2888210C (en) 2021-02-09
CN105209453A (zh) 2015-12-30

Similar Documents

Publication Publication Date Title
AR093017A1 (es) MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
HRP20192224T1 (hr) Inhibitori proteinske kinaze c i metode za njihovu primjenu
ES2666870T3 (es) Derivado de dispiropirrolidina
HRP20200274T1 (hr) Terapeutski aktivni spojevi i postupci njihove uporabe
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
AR092253A1 (es) Inhibidores de serina/treonina cinasa
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR090847A1 (es) Compuestos moduladores del receptor huerfano retinoideo (ror)
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
JP2014506599A5 (es)
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR091939A1 (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
AR123783A2 (es) Dispersión sólida amorfa que comprende un derivado de tetrazol y composición farmacéutica que comprende dicha dispersión
AR093512A1 (es) Derivados heterociclicos como moduladores de la actividad de cinasas
IN2014DN07283A (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure